Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. Executive Vice President Roxanne Lagano acquired 367.7875 phantom stock units on October 9, 2026, bringing her reported direct position to 31,314.6485 phantom stock units. The award is associated with 128.6593 underlying common shares. The units are settled in cash after her separation from service; she may transfer them to an alternative investment fund at any time, while Zoetis may limit transfer timing, frequency and permissibility.
Zoetis Inc. appointed Iris Knobloch to its Board of Directors, effective December 1, 2026. The Board will increase from 12 to 13 members on that date, and Knobloch has been appointed to serve on the Corporate Governance Committee. She is eligible to participate in Zoetis’s non-employee director compensation program, and the company will enter into its standard form of indemnification agreement with her. Zoetis stated that the appointment was not made pursuant to arrangements or understandings with a third party and that no related-party transactions reportable under Item 404(a) occurred between the company and Knobloch since the beginning of the last fiscal year.
Zoetis Inc. declared a $0.53 per-share dividend for the fourth quarter of 2026. The dividend will be paid on December 1, 2026, to holders of common stock of record as of the close of business on October 30, 2026.
Zoetis Inc. Executive Vice President Julie Fuller reported the exercise and settlement of 799.0707 restricted stock units on September 30, 2026, and acquired 799 common shares. She also had 274 common shares delivered or withheld for payment of exercise price or tax liability at $69.83 per share. Two reported RSU positions covered 3,666.9890 and 1,516.9563 underlying shares; one-third of each is scheduled to vest on the first, second and third grant anniversaries, subject to continued service.
Zoetis Inc. (ZTS) director Mark Stetter reported an acquisition of 342.3720 Phantom Stock Units on September 17, 2026 under the Zoetis Inc. Amended and Restated Non-Employee Director Deferred Compensation Plan. Each unit represents one share of Zoetis common stock and will be settled in cash after separation from service, bringing his total Phantom Stock Units to 880.1751.
Zoetis Inc. (symbol: ZTS) is the issuer of record for a Form 4 filing submitted to the SEC. SACCARO JAMES reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. (ZTS) reported that EVP, CFO & COO James Saccaro received a compensation-related grant of 81,063 Restricted Stock Units (RSUs) on August 31, 2026. Each RSU represents a contingent right to one share of Zoetis common stock, with one-third scheduled to vest on each of the first, second and third anniversaries of the grant date, subject to continued service and certain earlier-vesting conditions.
Zoetis Inc. (ticker ZTS) disclosed an initial statement of beneficial ownership for executive James Saccaro, who serves as EVP, CFO & COO. The filing reports that he currently has no securities beneficially held in Zoetis, with total direct holdings shown as 0 shares following the reported position.
Zoetis Inc. director Frank A. D'Amelio reported a bona fide gift of 6,650 shares of Zoetis common stock on 2026-08-07. The shares were transferred to the Frank A. D'Amelio 2-Year 2026 GRAT No. 3, where he is grantor, trustee and beneficiary, and are now reported as indirectly held. After the gift, he directly holds 14,808 shares and the trust holds 6,650 shares.
Zoetis Inc. has appointed James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. He will serve as the company’s principal financial officer and principal accounting officer, leading global finance and overseeing Global Manufacturing and Supply.
Under an offer letter dated July 31, 2026, Mr. Saccaro will receive a $1,000,000 annual base salary, a target annual bonus equal to 100% of base salary (with his 2026 bonus paid at target and prorated), and an annual long-term incentive opportunity of $5,000,000 in performance stock units, restricted stock units, and stock options. He is eligible for the Executive Severance Plan, relocation assistance, and standard executive benefits. He will also receive a one-time make-whole RSU award of $6,250,000, vesting in three equal annual installments, and a one-time make-whole cash award of $1,250,000 subject to repayment if his employment ends under certain circumstances within his first year.
Current CFO Wetteny Joseph will transition from Executive Vice President and Chief Financial Officer after August 16, 2026 to a non-officer role and will serve as a Special Advisor to the CEO on financial matters until early 2027. Until the earlier of February 28, 2027 or a mutually agreed termination date, he will continue his current salary, benefits, and equity vesting and remain eligible for a 2026 annual incentive award. Upon his termination date, he will receive separation benefits under Section 3.1 of the Executive Severance Plan, with equity treated as upon a “Restructuring Event.” The company states that his departure is not due to any disagreement on operations, policies, practices, accounting, or controls.